Related references
Note: Only part of the references are listed.Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations
Don Husereau et al.
BMC MEDICINE (2022)
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
Gabriel N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer
Vivian Le et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2021)
Cost Effectiveness of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Pre-/Perimenopausal, HR+ and HER2-Advanced Breast Cancer: A Canadian Healthcare Perspective
Daniel Stellato et al.
PHARMACOECONOMICS (2021)
Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women
Eunae Jeong et al.
FRONTIERS IN ONCOLOGY (2021)
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2-Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective
Daniel Stellato et al.
PHARMACOECONOMICS (2021)
Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2-Advanced or Metastatic Breast Cancer: A US Payer Perspective
Yingcheng Wang et al.
FRONTIERS IN MEDICINE (2021)
Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore
Lydia Loke et al.
CANCER REPORTS (2021)
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
Laura M Spring et al.
LANCET (2020)
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
Jennifer J. Gao et al.
LANCET ONCOLOGY (2020)
Endocrine-Resistant Breast Cancer: Mechanisms and Treatment
Andreas D. Hartkopf et al.
BREAST CARE (2020)
The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (HR plus )/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer
Jacopo Giuliani et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2020)
Cost-effectiveness of cancer drugs: Comparative analysis of the States and England
Avi Cherla et al.
ECLINICALMEDICINE (2020)
CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib
Tanja K. Eggersmann et al.
BIODRUGS (2019)
Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
Bingnan Zhang et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Palbociclib or Ribociclib in First-Line Treatment in Patients With Hormone Receptor-Positive/Human Epidermal Receptor 2-Negative Advanced or Metastatic Breast Cancer? A Perspective Based on Pharmacologic Costs
Jacopo Giuliani et al.
CLINICAL BREAST CANCER (2019)
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis
Mario Giuliano et al.
LANCET ONCOLOGY (2019)
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
G. N. Hortobagyi et al.
ANNALS OF ONCOLOGY (2018)
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Dennis J. Slamon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer
Neil O'Brien et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2-Advanced or Metastatic Breast Cancer: A US Payer Perspective
Rohit Mistry et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2018)
Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2- advanced or metastatic breast cancer in Spain
Elena Galve-Calvo et al.
CLINICOECONOMICS AND OUTCOMES RESEARCH (2018)
Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed
Wendie D. den Brok et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Cell-Cycle Therapeutics Come of Age
Matthew Ingham et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Cost-effectiveness Analysis Comparing Conventional, Hypofractionated, and Intraoperative Radiotherapy for Early-Stage Breast Cancer
Ashish A. Deshmukh et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
Raquel Torres-Guzman et al.
ONCOTARGET (2017)
Cost-effectiveness Analysis Comparing Conventional, Hypofractionated, and Intraoperative Radiotherapy for Early-Stage Breast Cancer
Ashish A. Deshmukh et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer
H. Mamiya et al.
ANNALS OF ONCOLOGY (2017)
PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy-Safety and Efficacy in Asian Patients
Hiroji Iwata et al.
JOURNAL OF GLOBAL ONCOLOGY (2017)
Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting
K. Matter-Walstra et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States
Angela B. Mariotto et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2017)
Cell cycle proteins as promising targets in cancer therapy
Tobias Otto et al.
NATURE REVIEWS CANCER (2017)
AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users
P. Vemer et al.
PHARMACOECONOMICS (2016)
Targeting CDK4 and CDK6: From Discovery to Therapy
Charles J. Sherr et al.
CANCER DISCOVERY (2016)
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses Second Panel on Cost-Effectiveness in Health and Medicine
Gillian D. Sanders et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Ping Chen et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Treating cancer with selective CDK4/6 inhibitors
Ben O'Leary et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
REAL-WORLD EVIDENCE ON HEALTH STATES UTILITIES IN IN METASTATIC BREAST CANCER PATIENTS: DATA FROM A RETROSPECTIVE PATIENT RECORD FORM STUDY AND A CROSS-SECTIONAL PATIENT SURVEY
S. Hudgens et al.
VALUE IN HEALTH (2016)
A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada
C. Beauchemin et al.
JOURNAL OF MEDICAL ECONOMICS (2016)
The changing role of ER in endocrine resistance
Agostina Nardone et al.
BREAST (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Asghar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts
Sonya C. Tate et al.
CLINICAL CANCER RESEARCH (2014)
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
Lawrence M. Gelbert et al.
INVESTIGATIONAL NEW DRUGS (2014)
Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome
Dorien J. A. Lobbezoo et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Cost-Effectiveness of Lapatinib plus Letrozole in Post-Menopausal Women with Hormone Receptor- and HER2-Positive Metastatic Breast Cancer
Thomas E. Delea et al.
BREAST CARE (2013)
INCIDENCE-BASED COST-OF-ILLNESS MODEL FOR METASTATIC BREAST CANCER IN THE UNITED STATES
Sonja V. Sorensen et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Neutropenia-Related Costs in Patients Treated with First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer
Michael E. Stokes et al.
JOURNAL OF MANAGED CARE PHARMACY (2009)
Health state utilities for metastatic breast cancer
A. Lloyd et al.
BRITISH JOURNAL OF CANCER (2006)
Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores
Janel Hanmer et al.
MEDICAL DECISION MAKING (2006)
Cyclin-dependent kinase pathways as targets for cancer treatment
GI Shapiro
JOURNAL OF CLINICAL ONCOLOGY (2006)
One thousand health-related quality-of-life estimates
TO Tengs et al.
MEDICAL CARE (2000)
Handling uncertainty in cost-effectiveness models
AH Briggs
PHARMACOECONOMICS (2000)
Share Paper
